| Project/Area Number |
23591633
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Kinki University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOSHIE Osamu 近畿大学, 医学部, 教授 (10166910)
HIGUCHI Tomonori 近畿大学, 医学部, 助教 (00448771)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 皮膚腫瘍学 / 抗がん剤耐性 / 成人T細胞白血病／リンパ腫（ATLL） / 皮膚T細胞リンパ腫（CTCL） / ABCG2/BCRP / c-Myb / Fra-2 / ATLL / トランスポーター / 成人T細胞白血病/リンパ腫 |
|---|
| Research Abstract |
Previously, we have shown that an AP-1 family member, FRA-2, is consistently expressed at high levels in Adult T-cell leukemia/lymphoma (ATLL) and up-regulates the expression of CCR4 as well as that of several proto-oncogenes such as c-Myb, MDM2, and BCL6. Here, we identified an ABC transporter, ABCG2/BCRP, as a target gene of c-Myb in mature T-cell lymphomas including ATLL and cutaneous T-cell lymphomas (CTCLs). We detected the transcripts and proteins of c-Myb and ABCG2/BCRP in ATLL cells. Furthermore, Ko143, a selective ABCG2/BCRP inhibitor, enhanced the antitumor activity of doxorubicin against ATLL cell lines. Taken together, our findings support the notion that the c-Myb-ABCG2/BCRP pathway plays a role in chemoresistance of mature T-cell lymphomas.
|
